Orally Disintegrating Tablets: A Patient-centric Dosage Form

Drug manufacturer Novo Nordisk said the approval establishes Ozempic as the most broadly indicated GLP-1 RA in its class.

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments.

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.

The company’s investments in Canada since 2023 have now resulted in the creation, or potential thereof, of 1200 new job positions.

Winners in this year's Pharmapack Awards include both commercial products and innovations that are shaping the future of pharmaceutical packaging.